Updates are available Correction dated 2018-07-12
Click to view Correction: https://doi.org/10.1007/s10096-018-3310-y
-
Authors
Stargardt, Tom
Eckmann, Christian
Bouza, Emilio
Rossolini, Gian Maria
Grossi, Paolo Antonio
-
Funding
Funding for this research was provided by:
Angelini Pharma
- License Information
-
More Information
Article History
Received: 23 February 2018
Accepted: 19 April 2018
First Online: 6 June 2018
Change Date: 12 July 2018
Change Type: Correction
Change Details: In the originally published article, the name of the last author was not correct. The name is Paolo Antonio Grossi, which is correctly shown above.
Compliance with ethical standards
:
: This article does not contain any studies with human participants or animals performed by any of the authors.
: Informed consent was obtained from all individual participants included in the study.
: TS is a member of advisory boards for Novo Nordisk, and Angelini and has received monetary compensation for participating in an advisory board and conducting a training course for Angelini, a manufacturer of dalbavancin. PAG is a member of advisory boards for Novartis, MSD, Paratek, Gilead, Angelini, Biotest, and BD and a member of the speakers’ bureau of MSD, Gilead, Biotest, Angelini. GMR has participated in advisory boards/speaker’s bureau for Accelerate, Achaogen, Angelini, Astra-Zeneca, Basilea, Biotest, Cepheid, Curetis, Elitech, Merck, Nordic Pharma, Pfizer, ThermoFisher, Zambon, and has received research grants from Accelerate, Alifax, Angelini, Astra-Zeneca, Basilea, Becton-Dickinson, bioMérieux, Biotest, Checkpoints, Elitech, Merck, Menarini, Nordic Pharma, Rempex, Zambon. EB has no conflict of interest to declare.
